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Abstract Cerebellar granule cells (CGCs) express the CB1
subtype of cannabinoid receptor. CB1 receptor agonists Win
55212-2, CP55940 and HU210 inhibit KCl-induced activation of
nitric oxide synthase (NOS) in CGCs. Win 55212-2 has no effect
on either basal NOS activity or on activation by N-methyl-D-
aspartate and its effect is abolished by pre-treatment of the cells
with pertussis toxin. The CB1 receptor antagonist/inverse agonist
SR141716A both reverses the effects of Win 55212-2 and
produces an increase in NOS activity that is additive with KCl.
These results support the hypothesis that activation of the CB1
receptor in CGCs results in a decreased influx of calcium in
response to membrane depolarization, resulting in a decreased
activation of neuronal NOS.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The psychoactive cannabinoid v9-tetrahydrocannabinol
(THC) [1] a¡ects the cellular function as a result of binding
to a G protein-coupled receptor [2]. This receptor, termed CB1
[3], is also activated by synthetic analogs of THC, including
CP55940 [2] and HU210 [4], by a series of aminoalkyl indoles,
including Win 55212-2 [5], and by the endocannabinoids N-
arachidonylethanolamine (AEA) [6] and 2-arachidonylglycerol
[7,8]. SR141716A has recently been identi¢ed as an antago-
nist/inverse agonist of the CB1 receptor [9,10].
The CB1 receptor is found in high density in many regions
of the brain, including the molecular layer of the cerebellum
[11]. Cerebellar granule cells (CGCs) in primary culture ex-
press the CB1 receptor and respond to CB1 receptor agonists
with a decrease in adenylyl cyclase activity and activation of
GTPase activity [12]. In addition, CB1 receptor activation in
CGCs results in inhibition of the opening of voltage-operated
calcium channels [13] in a manner very similar to CB1 inhib-
ition of N-type calcium channels in NG108 cells [14]. One
possible consequence of a reduction in calcium in£ux is de-
creased activation of various calcium dependent intracellular
processes, including the synthesis of nitric oxide (NO) by neu-
ronal NO synthase (nNOS). CGCs express high levels of
nNOS [15^17], which is activated in response to increased
intracellular calcium. This can be achieved through either de-
polarization-induced opening of voltage-operated calcium
channels or activation of N-methyl-D-aspartate (NMDA) glu-
tamatergic receptors [18]. The purpose of the studies described
herein was to test the hypothesis that CB1 receptor agonists
inhibit depolarization-induced activation of NOS as a result
of inhibition of calcium in£ux through voltage-operated cal-
cium channels.
2. Materials and methods
2.1. CGC primary culture
CGCs were prepared from 6^8 day old rat pups of either sex exactly
as described previously [19]. The cells were plated onto six well plates
coated with poly-D-lysine and were used for an assay at 7^10 days in
vitro.
2.2. [3H]SR141716A binding assay
CGCs were grown in 12 well dishes and were washed with 3U0.5
ml of warm HEPES bu¡er (154 mM NaCl, 5.6 mM KCl, 3.6 mM
NaHCO3, 5.6 mM glucose, 1.3 mM CaCl2 and 10 mM HEPES, pH
7.35) containing 0.1% fatty acid free bovine serum albumin (BSA).
Cells were incubated with [3H]SR141716A (0.05^2.75 nM) in 0.5 ml of
HEPES/BSA bu¡er for 30 min at 37‡C. After removal of the incuba-
tion bu¡er, cells were transferred to ice and washed three times with
1 ml of ice cold bu¡er containing BSA. After washing, the cells were
scraped into 0.5 ml of water and counted. Non-speci¢c binding was
determined in wells containing 10 WM THC. The resulting saturation
isotherms were ¢t to the single site binding equation using non-linear
regression (GraphPad Prism Software, San Diego, CA, USA).
2.3. Assay of NOS activity
NOS activity was measured using the conversion of [3H]arginine to
[3H]citrulline using a modi¢cation [20] of the method of Bredt and
Snyder [17]. Granule cells were pre-incubated with the cannabinoids
or vehicle and [3H]arginine (3 WCi) in HEPES/BSA bu¡er for 5 min at
37‡C. The stimulator (i.e. KCl or NMDA) or bu¡er alone was added
and the incubation was continued for 5 min. In some experiments,
1 WCi 45CaCl2 was added at the same time as the stimulator. After
5 min, the bu¡er was removed and the cells were washed three times
with 3 ml of cold bu¡er. The washed cells were scraped in 1 ml of
0.3 mM HClO4, the lysate was centrifuged and the supernatant was
neutralized with K2CO3. An aliquot of the supernatant was counted
for both 3H (to assess arginine uptake) and 45Ca (to assess calcium
entry during stimulation). A second aliquot of the supernatant was
placed onto columns containing Dowex AG 50W-X8 cation exchange
resin (sodium form). The £ow through and eluate following the addi-
tion of 2 ml of water were combined and counts per minute (cpm)
were determined. Studies using [14C]citrulline and [3H]arginine stand-
ards demonstrate that the columns retain over 98% of added arginine
and less than 7% of added citrulline.
2.4. Measurement of AEA synthesis by CGCs
AEA synthesis was measured using a precursor pre-loading method
similar to that described previously [21]. CGCs were pre-loaded with
[3H]arachidonic acid (AA) for 20^24 h and were then washed and
incubated with either bu¡er alone or with 35 mM KCl. After the
incubation, the cells and bu¡er were extracted with chloroform:me-
thanol (1:2) using established methods [22] and were separated using
reverse phase high pressure liquid chromatography (rpHPLC) using a
Nucleosil C-18 column (5 W, 4.6U250 mm). Solvent A (water) and
solvent B (acetonitrile containing 0.1% glacial acetic acid) were varied
from 50% A in B to 100% B over 40 min at a £ow rate of 1 ml/min.
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The column eluate was collected in 0.2 ml fractions and the radio-
activity determined.
2.5. Materials
[3H]Arginine (speci¢c activity 38.5 Ci/mmol), 45CaCl2 (22 mCi/mg),
[3H]AA (185 Ci/mmol) and [3H]AEA (223 Ci/mmol) were purchased
from Du Pont New England Nuclear (Boston, MA, USA).
[3H]SR141716A (speci¢c activity 40^50 Ci/mmol) was purchased
from Amersham Radiochemicals (Arlington Heights, IL, USA). Win
55212-2 was purchased from RBI Chemicals (Natick, MA, USA).
CP55940 was provided by P¢zer Central Research (Groton, CT,
USA), HU210 was a gift of Dr Raphael Mechoulam (Hebrew Uni-
versity, Israel), SR141716A was provided by Sano¢ Researche (Mont-
pellier, France) and v9-THC was obtained from the National Institute
on Drug Abuse (Rockville, MD, USA). All other drugs and chemicals
were of the highest grade possible and were purchased from standard
commercial sources.
2.6. Statistics
Treatment groups were compared using one way analysis of var-
iance followed by t-tests. A P value of less than 0.05 was used to
determine statistical signi¢cance.
3. Results
3.1. CGCs in primary culture express the CB1 receptor
As has been shown previously [12], CGCs at 7^10 days in
primary culture express the CB1 subtype of the cannabinoid
receptor. Membranes prepared from CGCs were positive for
the CB1 receptor in Western blot analysis (Fig. 1). CGCs
exhibit saturable binding of the selective CB1 receptor antag-
onist/inverse agonist, [3H]SR141716A (Fig. 1). The saturation
isotherms were ¢t to the single site binding equation and the
binding parameters were determined (KD 1.1 þ 0.3 nM and
Bmax 1.8 pmol/mg protein).
3.2. Depolarization-induced activation of NOS is reduced by
co-incubation with CB1 receptor agonists
Both KCl and NMDA increased the conversion of
[3H]arginine to [3H]citrulline (Table 1A). The e¡ects of both
stimuli were concentration-related, with maximal increases oc-
curring at 35 mM KCl and 100 WM NMDA. These agents
also produced increases in 45Ca in£ux during a 5 min incuba-
tion, although these increases did not reach statistical signi¢-
cance.
Incubation of the CGCs with the CB1 receptor agonist Win
55212-2 resulted in attenuation of KCl-induced NOS activa-
tion and 45Ca in£ux (Fig. 2). The IC50 value for Win 55212-2
inhibition of NOS activity was 1.88 WM (95% con¢dence in-
terval 1.2^2.9 WM) and the maximum inhibition was 66 þ 6%.
The IC50 value for Win 55212-2 inhibition of 45Ca was 0.90
WM (95% con¢dence interval 0.77^1.05 WM) and the maxi-
mum inhibition was 69 þ 2%. At a concentration of 10 WM,
Win 55212-2 had no e¡ect on the basal NOS activity or NOS
activation by NMDA and produced a slight decrease in 45Ca
in£ux in response to NMDA that did not reach statistical
signi¢cance (Table 1B).
Two other CB1 receptor agonists, CP55940 and HU210,
also attenuated depolarization-induced activation of NOS
and in£ux of calcium in CGCs. HU210 inhibited NOS activity
Fig. 1. CGC membranes bind [3H]SR141716A in a saturable manner. CGCs (8 days in vitro) were incubated with [3H]SR141716A for 30 min
at 37‡C, washed, lysed and the lysates were counted. Non-speci¢c binding was de¢ned using 10 WM THC and has been subtracted. Data shown
are the mean of two separate experiments. The line is the non-linear regression ¢t of the data to the single site binding equation. Inset: West-
ern blot of CGC membranes (lane 1) and rat forebrain membranes (lane 2) probed using an a⁄nity-puri¢ed polyclonal antibody to the CB1 re-
ceptor (provided by Dr Ken Mackie). Each lane contained 10 Wg of membrane protein. Numbers on the left represent the molecular weight.
Table 1A
Activation of NOS and calcium in£ux in CGCs
Stimulus Fractional conversion to citrulline Calcium in£ux (cpm)
Basal 0.142 þ 0.01 114 þ 51
KCl (35 mM) 0.248 þ 0.01* 213 þ 75
NMDA (100 WM) 0.191 þ 0.01* 294 þ 46
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with an IC50 value of 0.52 nM (95% con¢dence interval 0.41^
0.66 nM) and a maximal inhibition of 78 þ 4.2%. CP55940
inhibited NOS activity with an IC50 value of 7.3 nM (95%
con¢dence interval 3.7^14 nM) and a maximal inhibition of
79 þ 13%. The two agonists also inhibited 45Ca in£ux. At 3 nM
HU210, KCl-induced 45Ca in£ux was reduced by 85.5 þ 14.5%
(n = 3) and at 10 nM CP55940, KCl-induced 45Ca in£ux was
reduced by 100% (n = 2).
3.3. SR141716A increases NOS activity in CGCs
SR141716A is a CB1 receptor antagonist [23,24]. At a con-
centration of 100 nM, SR141716A produced a signi¢cant in-
crease in the formation of [3H]citrulline from [3H]arginine, an
increase that was approximately equal to the increase pro-
duced by 35 mM KCl (Fig. 3A). When SR141716A was added
together with KCl, the e¡ects of the two compounds were
additive. When SR141716A was added together with Win
55212-2 and KCl, NOS activity was equal to the activity
seen in the presence of KCl alone. That is, both SR141716A
activation and Win 55212-2 inhibition were reversed. At a
concentration of 300 nM, SR141716A doubled the amount
of 45Ca in£ux compared to a vehicle control (data not shown).
The EC50 value for SR141716A was 15 nM (95% con¢dence
interval 0.6^367 nM).
The e¡ects of SR141716A could be due to inhibition of the
actions of an endogenous CB1 agonist that is released when
the cells are depolarized by KCl. To test this possibility,
CGCs were pre-loaded with [3H]AA for 24 h, then incubated
with either bu¡er alone or bu¡er containing 35 mM KCl.
After the incubation, cellular and media lipids were extracted
and the radiolabelled species separated using rpHPLC. No
radiolabelled species that co-migrated with [3H]AEA were de-
tected in either the bu¡er (data not shown) or KCl-treated
(Fig. 4) CGCs.
Table 1B
E¡ects of Win 55212-2 on NOS activity and calcium in£ux in CGCs
Stimulus Fractional conversion to citrulline Calcium in£ux (cpm)
Control Win 55212-2 (10 WM) Control Win 55212-2 (10 WM)
Basal 0.138 þ 0.01 0.132 þ 0.01 88 þ 24 80 þ 26
100 WM NMDA 0.181 þ 0.01 0.174 þ 0.02 304 þ 60* 270 þ 48*
CGCs were maintained in culture for 8^12 days and were incubated with [3H]arginine for 5 min prior to the addition of 45Ca and either bu¡er
(‘Basal’), KCl or NMDA. The incubation was allowed to proceed for 5 additional min at which time the cells were washed and cell lysates
were analyzed for [3H]citrulline, [3H]arginine or 45Ca as described in Section 2. Data are shown þ S.E.M. Each value is the mean of 4^5 experi-
ments carried out in duplicate.
*Signi¢cantly di¡erent from basal activity or calcium in£ux at P6 0.05 using Dunnett’s t-test.
Fig. 2. Win 55212-2 inhibits both KCl-induced NOS activity and
calcium in£ux in CGCs. CGCs (8 days in vitro) were pre-incubated
with both Win 55212-2 (or DMSO vehicle) and [3H]arginine for
5 min at 37‡C. KCl (¢nal concentration 35 mM) was added along
with 45Ca and the incubation was continued for 5 min. NOS activ-
ity was determined from the conversion of [3H]arginine to
[3H]citrulline and 45Ca in£ux was determined in the washed cell ly-
sates. Shown are the mean data from four experiments, vertical lines
represent S.E.M. Lines are the best ¢t of the data to the sigmoidal
concentration-response curve. Control values were determined in
cells pre-treated with DMSO.
Fig. 3. A: CGCs were pre-incubated with either Win 55212-2,
SR141716A, their combination or DMSO vehicle and [3H]arginine
for 5 min at 37‡C. B: Cells were pre-treated with pertussis toxin
(0.1 Wg/well) for 24 h, followed by washing and pre-treatment with
Win 55212-2 or DMSO and [3H]arginine for 5 min at 37‡C. In
both, KCl (¢nal concentration 35 mM) was added and the incuba-
tion was continued for 5 min. NOS activity was determined from
the conversion of [3H]arginine to [3H]citrulline. NOS activity in the
absence of KCl has been subtracted. Each bar represents the mean
of three experiments, lines represent S.E.M. * indicates signi¢cantly
di¡erent from KCl-treated cells pre-incubated with DMSO with
P6 0.05. 2 indicates signi¢cantly increased over basal activity.
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3.4. Reversal of the e¡ects of Win 55212-2 by pertussis toxin
CGCs were pre-treated with pertussis toxin (0.1 Wg/well) for
24 h. Control cells received media alone. Pertussis toxin pre-
treatment had no signi¢cant e¡ect on NOS activation by
35 mM KCl but reversed Win 55212-2 inhibition of KCl-
stimulated NOS activity (Fig. 3B).
4. Discussion
In agreement with the work of others [12,25,26], we have
found that CGCs express a functional CB1 receptor in pri-
mary culture. Activation of the CB1 receptor in CGCs by the
synthetic cannabinoid Win 55212-2 results in decreased KCl-
mediated activation of NOS. In light of the well documented
ability of CB1 receptor agonists to reduce the calcium current
through voltage-operated calcium channels [14,27,28], it is our
hypothesis that CB1 attenuation of NOS activity occurs as a
result of inhibition of the in£ux of calcium in response to
KCl. In support of this hypothesis, neither basal NOS activity
(i.e. unstimulated) nor NOS activation by NMDA are a¡ected
by Win 55212-2, suggesting that inhibition occurs only when
activator calcium enters the cells via VOCCs. In addition, Win
55212-2 inhibits 45Ca in£ux into CGCs in response to KCl but
not NMDA. The latter ¢nding is in disagreement with the
data of Hampson and coworkers who found that AEA, via
the CB1 receptor, reduced the in£ux of calcium into cerebellar
slices [29]. Taken together, these data suggest that activation
of the CB1 receptor of CGCs reduces the synthesis of NO in
response to depolarization via inhibition of calcium entry
through VOCCs.
Win 55212-2 inhibition of KCl-stimulated NOS activity
is mimicked by two other potent CB1 agonists, CP55940
and HU210. The potency order of the agonists (HU210s
CP55940sWin 55212-2) is consistent with other studies
[30]. However, Win 55212-2 is somewhat less potent in this
assay than in other assays of CB1 receptor activation. For
example, Win 55212-2 inhibits adenylyl cyclase in CGCs
with an IC50 value of 0.1 WM [12], a concentration 10-fold
lower than the IC50 values found in the present study. One
possible explanation for the di¡erence is that the present in-
cubations were carried out with BSA in the bu¡er as a dis-
persing agent for the cannabinoids, while the earlier study
used only DMSO as a vehicle [12].
SR141716A activated NOS and increased the in£ux of ex-
tracellular calcium, e¡ects that were reversed by Win 55212-2.
Since the CB1 receptor is the only known site of action of low
concentrations of SR141716A, the most likely explanation for
these data is that SR141716A reverses or inhibits tonic acti-
vation of the CB1 receptor. Tonic activation of the CB1 re-
ceptor could either be due to the presence of an endogenous
CB1 agonist, such as AEA, or the result of constitutive activ-
ity of the CB1 receptor [31]. Our evidence does not support
the ¢rst possibility as 35 mM KCl did not increase the syn-
thesis of AEA in CGCs. In support of the second possibility,
SR141716A has been shown in several studies to act as an
inverse agonist of the CB1 receptor [9,32]. Inverse agonists are
de¢ned as ligands that occupy the ligand binding site of a
receptor and decrease receptor coupling to G proteins
[33,34]. As a result, inverse agonists can produce cellular
changes that are opposite to those of agonists. Our data sug-
gest that SR141716A is acting as an inverse agonist of the
CB1 receptor in CGCs and thereby imply that the CB1 recep-
tor functions as a brake on the activation of NOS in the
absence of agonist. However, we cannot completely rule out
either functional antagonism between Win 55212-2 and
SR141716A that is not mediated completely by the CB1 re-
ceptor or SR141716A antagonism of an endogenous CB1 li-
gand that is not AEA.
Granule cell axons in vivo form the parallel ¢bers of the
molecular layer of the cerebellum. The target of the parallel
¢bers are Purkinje cells, the major out£ow cell of the cerebel-
lum. The parallel ¢ber-Purkinje cell synapse is glutamatergic
and has been studied as a model of synaptic plasticity. A
recent report by Levenes and coworkers demonstrates that
Win 55212-2, acting via the CB1 receptor, inhibits glutama-
tergic transmission at parallel ¢ber-Purkinje cell synapses via
a pre-synaptic e¡ect [35]. The most likely mechanism for this
e¡ect is inhibition of pre-synaptic VOCCs, resulting in a de-
crease in the probability of glutamate release. Win 55212-2
also reduces the induction of long term depression at this
synapse via a pre-synaptic e¡ect. The authors of that study
suggest that inhibition of NO synthesis by Win 55212-2 may
play a role in this physiologic e¡ect [35]. Our results are con-
sistent with this suggestion.
There have been several other studies of the interactions of
the cannabinoids with NOS which suggest that the actions of
the cannabinoids on NOS may vary in di¡erent cell types. The
cannabinoids anandamide and CP55940 have been shown to
increase NO production by human monocytes and inverte-
brate immunocytes [36]. This e¡ect is blocked by
SR141716A, supporting a role of the CB1 receptor in this
action. Interestingly, a homologue of the CB1 receptor has
recently been identi¢ed in the leech central nervous system
that also regulates NOS activity [37]. The synthesis of NO
by NOS in human endothelial cells is also increased by anan-
damide [38], possibly due to CB1-mediated increase in the
release of intracellular calcium [39].
In summary, these data suggest that the neuronal CB1 re-
ceptor plays a role in the regulation of NO synthesis. In light
of the data that SR141716A increases NOS activity, we sug-
gest that the CB1 receptor is constitutively active and serves as
Fig. 4. Depolarization of CGCs does not a¡ect the concentration of
[3H]AEA in the cultures. CGCs were pre-incubated with [3H]AA for
20 h prior to stimulation with bu¡er containing 35 mM KCl. Fol-
lowing the stimulation, lipids were extracted from the cells and
media and were separated using rpHPLC. An arrow indicates the
fraction at which standard [3H]AEA was detected. Shown is a
representative from three similar experiments.
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a brake on calcium entry in response to depolarization. As a
result, CB1 receptor agonists can further reduce NOS activity
while the cell itself, via changes in the synthesis or activity of
CB1 receptors themselves, can increase (i.e. disinhibit) NOS
activity. In light of the widespread role of NO as a modula-
tory agent in the brain, it is likely that NOS inhibition plays a
role in the overall e¡ects of cannabinoids on the brain func-
tion.
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